- Home
- SHPH vs NDRA Comparison
SHPH vs NDRA Comparison
Compare SHPH & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- NDRA
- Stock Information
- Founded
- SHPH 2012
- NDRA 2007
- Country
- SHPH United States
- NDRA United States
- Employees
- SHPH N/A
- NDRA N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SHPH Health Care
- NDRA Health Care
- Exchange
- SHPH Nasdaq
- NDRA Nasdaq
- Market Cap
- SHPH 2.2M
- NDRA N/A
- IPO Year
- SHPH 2022
- NDRA 2017
- Fundamental
- Price
- SHPH $0.41
- NDRA $3.92
- Analyst Decision
- SHPH
- NDRA Strong Buy
- Analyst Count
- SHPH 0
- NDRA 1
- Target Price
- SHPH N/A
- NDRA $14,000.00
- AVG Volume (30 Days)
- SHPH 260.4K
- NDRA 8.4K
- Earning Date
- SHPH 05-12-2025
- NDRA 03-31-2025
- Dividend Yield
- SHPH N/A
- NDRA N/A
- EPS Growth
- SHPH N/A
- NDRA N/A
- EPS
- SHPH N/A
- NDRA N/A
- Revenue
- SHPH N/A
- NDRA N/A
- Revenue This Year
- SHPH N/A
- NDRA N/A
- Revenue Next Year
- SHPH N/A
- NDRA N/A
- P/E Ratio
- SHPH N/A
- NDRA N/A
- Revenue Growth
- SHPH N/A
- NDRA N/A
- 52 Week Low
- SHPH $0.33
- NDRA $3.15
- 52 Week High
- SHPH $4.71
- NDRA $717.50
- Technical
- Relative Strength Index (RSI)
- SHPH 33.79
- NDRA 42.85
- Support Level
- SHPH $0.35
- NDRA $3.96
- Resistance Level
- SHPH $0.41
- NDRA $4.36
- Average True Range (ATR)
- SHPH 0.05
- NDRA 0.31
- MACD
- SHPH 0.01
- NDRA 0.04
- Stochastic Oscillator
- SHPH 33.96
- NDRA 33.05
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.